Amarin Corporation plc is a pharmaceutical company focused on cardiovascular therapeutics. The company's primary product is VASCEPA, a prescription omega-3 fatty acid medication indicated as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. VASCEPA is the company's principal revenue driver and is sold through wholesalers, selected regional wholesalers, and specialty pharmacy providers.
The company maintains a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on VASCEPA's active pharmaceutical ingredient, EPA, extending its commercial reach internationally. The company operates across the United States, Europe, and other international markets.
Amarin was incorporated in the United Kingdom in 1989 and is headquartered in Dublin, Ireland, where it is listed on the Nasdaq exchange. The company operates at a relatively small scale relative to major pharmaceutical manufacturers, with a market capitalization of approximately $0.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.20 | $-0.20 | -33.3% | |
| 2023 | $-0.15 | $-0.15 | +42.3% | |
| 2022 | $-0.26 | $-0.26 | -1400.0% | |
| 2021 | $0.02 | $0.02 | +140.0% | |
| 2020 | $-0.05 | $-0.05 | -350.0% | |
| 2019 | $0.02 | $0.02 | +118.2% | |
| 2018 | $-0.11 | $-0.11 | -37.5% | |
| 2017 | $-0.08 | $-0.08 | +20.0% | |
| 2016 | $-0.10 | $-0.10 | +16.7% | |
| 2015 | $-0.12 | $-0.12 | -9.1% | |
| 2014 | $-0.11 | $-0.11 | +59.3% | |
| 2013 | $-0.27 | $-0.09 | -285.7% | |
| 2012 | $-0.07 | $-0.07 | -158.3% | |
| 2011 | $0.12 | $0.14 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-12 | 0000950170-25-037620 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0000950170-24-022636 | SEC ↗ |
| 2022-12-31 | 2023-03-01 | 0000950170-23-005336 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0000950170-22-002401 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001564590-21-008382 | SEC ↗ |
| 2019-12-31 | 2020-02-25 | 0001564590-20-006390 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001564590-19-004655 | SEC ↗ |
| 2017-12-31 | 2018-02-27 | 0001564590-18-003389 | SEC ↗ |
| 2016-12-31 | 2017-03-01 | 0001193125-17-065969 | SEC ↗ |
| 2015-12-31 | 2016-02-25 | 0001193125-16-476872 | SEC ↗ |
| 2014-12-31 | 2015-03-03 | 0001193125-15-075070 | SEC ↗ |
| 2013-12-31 | 2014-02-27 | 0001193125-14-072975 | SEC ↗ |
| 2012-12-31 | 2013-02-28 | 0001193125-13-084191 | SEC ↗ |
| 2011-12-31 | 2012-02-29 | 0001193125-12-089181 | SEC ↗ |